Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Eos Energy Enterprises Inc (EOSE) Price & Performance

Adaptive Biotechnologies CorpTrade
Eos Energy Enterprises IncTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Eos Energy Enterprises Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.63 (market cap $4.05B), while Eos Energy Enterprises Inc trades at $4.19 (market cap $1.47B). The key difference: Adaptive Biotechnologies Corp is far larger — about 2.8× Eos Energy Enterprises Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Eos Energy Enterprises Inc nearer its low. Which is the better fit depends on your goals.

ADPTEOSE
Market Cap
$4.05B$1.47B
Sector
HealthEnergy
52-Week High
$25.45$19.19
52-Week Low
$12.15$3.14
Enterprise Value
$4.12B$1.81B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.

Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE